BioSpace News Archive

XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the addition of Mark Ziats, M.D. Ph.D. as Medical Director.

USAntibiotics, the sole licensed American maker of penicillin-based Amoxicillin and Amoxil Clavulanate, the popular antibiotics commonly known as Amoxil® and Augmentin®, today reopened its Bristol, Tenn. manufacturing facility, which had slipped into bankruptcy and ceased operations last year.

September marks “National Muscular Dystrophy Awareness Month,” an annual observance that raises awareness and drives critical fundraising for more than 300,000 families across the nation who are living with muscular dystrophy, ALS, and related neuromuscular diseases.

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, announced today that its Evolent Care Partners (ECP) business unit saved Medicare more than $21 million in 2020, its inaugural year as the owner of an accountable care organization (ACO).

Epitome Risk announces its at-home neutralizing antibody test is now sold online.

Octapharma USA today announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded seven years of marketing exclusivity for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis (DM).

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced its half-year 2021 interim results, along with corporate progress update.

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that its board directors resolved to repurchase shares worth up to HK$100 million in the open market from time to time.

BIOMEDevice Boston, the east coast’s premier event that showcases emerging technologies from cutting-edge engineers, innovative thinkers, and business leaders who impact the progression of the world’s biomedical field, today announced the keynote lineup featuring world-renowned speakers from Brigham & Women’s Hospital and MEDX Ventures Group.

PreciseMDX, the leading end-to-end digital health platform, introduces a cloud-based solution that automates and simplifies the diagnostic testing experience, empowering labs to deliver a transformative journey to providers and patients.